The changing landscape of biosimilars in rheumatology

Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, L. Gulácsi, Jonathan Kay, Tore K. Kvien, Josef Smolen, Yoshiya Tanaka, Gerd R. Burmester

Research output: Article

84 Citations (Scopus)

Abstract

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and healtheconomic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
DOIs
Publication statusAccepted/In press - márc. 8 2016

Fingerprint

Biosimilar Pharmaceuticals
Rheumatology
Pharmacovigilance
Cost Savings
Rheumatic Diseases
Marketing
Costs
Monoclonal Antibodies
Economics
Health
Databases
Guidelines
Physicians
Safety
Costs and Cost Analysis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Dörner, T., Strand, V., Cornes, P., Gonçalves, J., Gulácsi, L., Kay, J., ... Burmester, G. R. (Accepted/In press). The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209166

The changing landscape of biosimilars in rheumatology. / Dörner, Thomas; Strand, Vibeke; Cornes, Paul; Gonçalves, João; Gulácsi, L.; Kay, Jonathan; Kvien, Tore K.; Smolen, Josef; Tanaka, Yoshiya; Burmester, Gerd R.

In: Annals of the Rheumatic Diseases, 08.03.2016.

Research output: Article

Dörner, T, Strand, V, Cornes, P, Gonçalves, J, Gulácsi, L, Kay, J, Kvien, TK, Smolen, J, Tanaka, Y & Burmester, GR 2016, 'The changing landscape of biosimilars in rheumatology', Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209166
Dörner, Thomas ; Strand, Vibeke ; Cornes, Paul ; Gonçalves, João ; Gulácsi, L. ; Kay, Jonathan ; Kvien, Tore K. ; Smolen, Josef ; Tanaka, Yoshiya ; Burmester, Gerd R. / The changing landscape of biosimilars in rheumatology. In: Annals of the Rheumatic Diseases. 2016.
@article{07f1340bf34a497fad61747ad2c5a333,
title = "The changing landscape of biosimilars in rheumatology",
abstract = "Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and healtheconomic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.",
author = "Thomas D{\"o}rner and Vibeke Strand and Paul Cornes and Jo{\~a}o Gon{\cc}alves and L. Gul{\'a}csi and Jonathan Kay and Kvien, {Tore K.} and Josef Smolen and Yoshiya Tanaka and Burmester, {Gerd R.}",
year = "2016",
month = "3",
day = "8",
doi = "10.1136/annrheumdis-2016-209166",
language = "English",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - The changing landscape of biosimilars in rheumatology

AU - Dörner, Thomas

AU - Strand, Vibeke

AU - Cornes, Paul

AU - Gonçalves, João

AU - Gulácsi, L.

AU - Kay, Jonathan

AU - Kvien, Tore K.

AU - Smolen, Josef

AU - Tanaka, Yoshiya

AU - Burmester, Gerd R.

PY - 2016/3/8

Y1 - 2016/3/8

N2 - Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and healtheconomic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.

AB - Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and healtheconomic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval.

UR - http://www.scopus.com/inward/record.url?scp=84960851952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960851952&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2016-209166

DO - 10.1136/annrheumdis-2016-209166

M3 - Article

C2 - 26964144

AN - SCOPUS:84960851952

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -